Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

, DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

05:34
09/25/17
09/25
05:34
09/25/17
05:34

Exelixis: ESAX-HTN pivotal study in essential hypertension met primary objective

Exelixis (EXEL) announced that its partner Daiichi Sankyo (DSNKY) has reported positive top-line results from a phase 3 pivotal trial of esaxerenone, a product of the companies' prior research collaboration, in patients with essential hypertension in Japan. With the trial achieving its primary endpoint, Daiichi Sankyo has communicated its intention to submit a Japanese regulatory application for esaxerenone for an essential hypertension indication in the first quarter of 2018. In March 2006, Daiichi Sankyo and Exelixis entered into a research collaboration agreement to discover, develop and commercialize novel therapies targeting the mineralocorticoid receptor, or MR. Under the terms of the agreement, Daiichi Sankyo has exclusive global development, manufacturing, and commercialization rights for the compounds. Esaxerenone, a non-steroidal, selective novel MR blocker, is one of the compounds identified during the research collaboration, and has subsequently been developed by Daiichi Sankyo. As esaxerenone advances, Exelixis is eligible for substantial clinical development, regulatory, and commercialization milestones, as well as double-digit royalties on sales. The positive trial, ESAX-HTN, is a randomized, double-blind, three-arm parallel group comparison study evaluating the efficacy and safety of esaxerenone versus eplerenone in patients with essential hypertension in Japan. The primary endpoint is sitting systolic blood pressure, or SBP, / diastolic blood pressure, or DBP, change from baseline after 12 weeks of treatment, and the secondary endpoint is mean 24-hour SBP/DBP change from baseline after 12 weeks of treatment. The trial enrolled 1,001 patients at approximately 40 clinical sites in Japan. Preliminary and ongoing analyses have indicated no significant safety concerns in the ESAX-HTN study. Daiichi Sankyo plans to disclose the detailed study results at future scientific meetings.

EXEL

Exelixis

$24.47

-3.54 (-12.64%)

DSNKY

Daiichi Sankyo

$23.03

0.17 (0.74%)

  • 25

    Sep

  • 25

    Sep

EXEL Exelixis
$24.47

-3.54 (-12.64%)

09/12/17
NEED
09/12/17
NO CHANGE
NEED
Exelixis data positive, says Needham
Needham analyst Chad Messer says that a study on Exelixis' advanced renal cell carcinoma treatment, Cabozantinib, indicated that the drug's positive impact on progression free survival was greater than shown in previous studies. The analyst thinks that all of the data on Cabozantinib has been positive, and Messer continues to believe that checkpoint inhibitors will be used in conjunction with the drug, rather than as a substitute for it. He keeps a $30 price target and a Buy rating on Exelixis.
09/14/17
RBCM
09/14/17
INITIATION
Target $32
RBCM
Outperform
Exelixis initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Exelixis with an Outperform and a $32 price target telling investors cabozantinib is poised to become an oncology blockbuster and sees scarcity value as a standalone company. MaCKay sees expansion into 1L kidney cancer and liver cancer leading to $3B+ in additional peak global sales potential.
09/22/17
LEER
09/22/17
DOWNGRADE
LEER
Market Perform
Exelixis downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Exelixis to Market Perform and lowered its price target to $28 from $34 saying fundamentals are strong but shares are fairly valued. Schmidt remains constructive on the long-term potential of Cabometyx in combination with immune-checkpoint inhibitors, but believes the commercial opportunity in HCC could be smaller than anticipated and lowered his long-term forecast below consensus.
09/22/17
RHCO
09/22/17
NO CHANGE
RHCO
Exelixis trial likely to be continued, says SunTrust
SunTrust analyst Peter Lawson says that the trial of Exelixis' cabozantinib.in liver cancer will most likely be continued through 2018. He views this scenario as "neutral to negative" for the stock. However, he recommends buying the shares on any weakness, citing what he sees as upcoming positive catalysts, including opportunities in bladder, breast and lung, new data, "and potential revenue beats from broadening use and 1H18 label expansion." He keeps a $33 price target and a Buy rating on the shares.
DSNKY Daiichi Sankyo
$23.03

0.17 (0.74%)

TODAY'S FREE FLY STORIES

TSS

TSYS

, T

AT&T

09:16
10/17/17
10/17
09:16
10/17/17
09:16
Hot Stocks
TSYS appoints Realogy CEO, AT&T Business CEO to board »

TSYS (TSS) announced the…

TSS

TSYS

T

AT&T

RLGY

Realogy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 01

    Nov

  • 29

    Nov

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

09:15
10/17/17
10/17
09:15
10/17/17
09:15
Recommendations
Bombardier, Airbus, Boeing analyst commentary  »

Bombardier, Airbus…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BA

Boeing

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SCG

Scana

09:15
10/17/17
10/17
09:15
10/17/17
09:15
Hot Stocks
Scana reports subpoena from SEC related to nuclear project probe »

Scana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ULTA

Ulta Beauty

$193.70

-4.88 (-2.46%)

, AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

09:15
10/17/17
10/17
09:15
10/17/17
09:15
Recommendations
Ulta Beauty, Amazon.com analyst commentary  »

Ulta Beauty recent…

ULTA

Ulta Beauty

$193.70

-4.88 (-2.46%)

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

HOG

Harley-Davidson

09:14
10/17/17
10/17
09:14
10/17/17
09:14
Hot Stocks
Harley-Davidson says no longer expects international growth in 2H17 »

Says remains committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SATS

EchoStar

$54.45

-0.85 (-1.54%)

, LVLT

Level 3

09:13
10/17/17
10/17
09:13
10/17/17
09:13
Hot Stocks
EchoStar subsidiary offers telecommunications services through Level 3 contract »

EchoStar's (SATS)…

SATS

EchoStar

$54.45

-0.85 (-1.54%)

LVLT

Level 3

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

09:11
10/17/17
10/17
09:11
10/17/17
09:11
Hot Stocks
UnitedHealth sees FY18 adj. EPS in-line with consensus »

Consensus $10.85. Expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SRAX

Social Reality

$2.87

-0.19 (-6.21%)

09:11
10/17/17
10/17
09:11
10/17/17
09:11
Conference/Events
Social Reality to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 14

    Nov

HOG

Harley-Davidson

09:11
10/17/17
10/17
09:11
10/17/17
09:11
Hot Stocks
Breaking Hot Stocks news story on Harley-Davidson »

Harley-Davidson says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

09:10
10/17/17
10/17
09:10
10/17/17
09:10
General news
FX Action: The dollar »

FX Action: The dollar…

TDC

Teradata

$32.97

-0.24 (-0.72%)

, GE

General Electric

$23.36

0.38 (1.65%)

09:09
10/17/17
10/17
09:09
10/17/17
09:09
Hot Stocks
GE Aviation and Teradata partner for airline analytics solutions »

GE (GE) Aviation and…

TDC

Teradata

$32.97

-0.24 (-0.72%)

GE

General Electric

$23.36

0.38 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 02

    Nov

V

Visa

$108.30

-0.36 (-0.33%)

09:08
10/17/17
10/17
09:08
10/17/17
09:08
Hot Stocks
Visa and Billtrust partner for B2B virtual card acceptance »

Visa and Billtrust today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Nov

DGX

Quest Diagnostics

$91.53

0.47 (0.52%)

09:07
10/17/17
10/17
09:07
10/17/17
09:07
Recommendations
Quest Diagnostics analyst commentary  »

Quest Diagnostics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

HOG

Harley-Davidson

09:07
10/17/17
10/17
09:07
10/17/17
09:07
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson Q3 beat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HOG

Harley-Davidson

$46.57

-0.05 (-0.11%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
Harley-Davidson says Q3 international performance down »

Sees tremendous interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AMDA

Amedica

$0.29

-0.01049 (-3.46%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
Amedica receives positive Nasdaq listing decision »

Amedica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$13.51

0.31 (2.35%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
MiMedx warns of fake emails »

MiMedx Group warned that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 08

    Nov

  • 09

    Nov

  • 10

    Nov

  • 13

    Nov

  • 14

    Nov

BUD

AB InBev

$125.72

0.36 (0.29%)

09:05
10/17/17
10/17
09:05
10/17/17
09:05
Hot Stocks
Anheuser-Busch, Convoy sign multiyear partnership to advance shipping operations »

Anheuser-Busch and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

09:05
10/17/17
10/17
09:05
10/17/17
09:05
General news
U.S. equities are trading sideways »

U.S. equities are trading…

BKI

Black Knight

$46.85

0.05 (0.11%)

09:04
10/17/17
10/17
09:04
10/17/17
09:04
Hot Stocks
Black Knight, Homebot announce strategic alliance »

Black Knight announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MS

Morgan Stanley

$48.94

0.64 (1.33%)

09:03
10/17/17
10/17
09:03
10/17/17
09:03
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley CEO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

CELG

Celgene

$136.71

0.25 (0.18%)

09:03
10/17/17
10/17
09:03
10/17/17
09:03
Initiation
Celgene initiated  »

Celgene initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Roku expands further into Latin America, to launch two players in region »

Roku, Inc. announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEOT

Neothetics

$0.52

-0.0206 (-3.81%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Neothetics, Evofem Biosciences announce all-stock merger »

Neothetics (NEOT) and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:01
10/17/17
10/17
09:01
10/17/17
09:01
Hot Stocks
Roku launches Roku Express in Canada »

Roku, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.